Relay Therapeutics, Inc. (RLAY)
| Market Cap | 2.55B |
| Revenue (ttm) | 85.12M |
| Net Income (ttm) | -261.14M |
| Shares Out | 108.55M |
| EPS (ttm) | -2.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 403,804 |
| Open | 23.98 |
| Previous Close | 23.64 |
| Day's Range | 23.44 - 25.18 |
| 52-Week Range | 23.40 - 62.95 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 50.50 (+114.6%) |
| Earnings Date | Nov 10, 2021 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth facto...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is 50.50, which is an increase of 114.62% from the latest price.
News
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9...
Biotech: Interest ‘in vaccine stocks will probably wane,' strategist says
Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent an...
RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer...
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...
Why Relay Therapeutics Is Up 30% This Week
Interim trial data suggests this innovative biotech start-up is on the right track.
Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member
EMERYVILLE, Calif.--(BUSINESS WIRE)--Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, ann...
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...
Relay Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...
Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial
Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer) and multiple other solid tumors. The data were share...
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4)
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selectiv...
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular ...
Relay Therapeutics to host a conference call on October 8th at 12:30 pm E.T. Relay Therapeutics to host a conference call on October 8th at 12:30 pm E.T.
Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in fireside chats at the Goldman Sachs 42nd Annual Global Healthcare Conference on...
Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on Th...
Relay Therapeutics Reports First Quarter 2021 Financial Results
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge ...
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
Dr. Riley brings extensive experience in artificial intelligence with a focus on drug discovery Dr. Riley brings extensive experience in artificial intelligence with a focus on drug discovery
Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, M...
Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O'Meara and Charles Ferté
Ms. O'Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease Ms. O'Meara and Dr. Ferté bring extensive experience in drug development across oncology and ...
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Me...
Relay Therapeutics' leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields
Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021
Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting
RLY-4008 demonstrates strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models RLY-4008 demonstrates strong activity against known clinical on-tar...
Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursda...
Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4...